| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present new efficacy data on brilaroxazine in an animal model of idiopathic pulmonary fibrosis as part of a late-breaking poster presentation at the 2024 American Thoracic Society (ATS) International Conference, to be held in San Diego, CA, May 17-22, 2024.
Details for the poster presentation can be found below:
Title: Effectiveness of brilaroxazine on functional and underlying pathological inflammation and fibrosis parameters in bleomycin-induced idiopathic pulmonary fibrosis model using male sprague dawley rats
Poster Number: 15059
Session (C73): Thematic Poster Session - Preclinical modeling of pulmonary inflammation and emphysema
Date: Tuesday, May 21, 2024
Time: 9:15am – 4:15pm PT
Presenter: Laxminarayan Bhat, Reviva Pharmaceuticals
Location: San Diego Convention Center, San Diego, CA
Posted In: RVPH
